Insurance companies are hurting from the high cost of hepatitis C drug Sovaldi. Arthur Caplan, NYU Langone Medical Center, and CNBC's Bertha Coombs, share their opinions.» Read More
CNBC's Meg Tirrell reports which biotech companies are working on what analysts say could be the next big biotech catalyst known as NASH, or nonalcoholic steatohepatitis.
David Dinenberg, Kind Banking founder and CEO, provides insight to his business model of providing financing to the new legal pot industry.
The FDA approved MannKind's inhaled insulin drug Afrezza. CNBC's Meg Tirrell has the details of the approval.
WASHINGTON, June 25- The senior U.S. senator from Illinois said on Wednesday he hopes that Walgreen Co, the major drugstore chain based in his state, will not relocate its tax home base to Switzerland, as some of the company's investors favor.
June 24- Walgreen Co, the largest U.S. drugstore operator, withdrew its profit and revenue forecasts for 2016, saying it had yet to work out several aspects of its planned acquisition of European drug retailer Alliance Boots Holdings Ltd..
June 24- Walgreen Co, the largest U.S. drug retailer, reported a lower-than-expected quarterly profit and said it was withdrawing its forecast for 2016 as it moves toward the complete acquisition of Alliance Boots Holdings Ltd. Walgreen said it would update investors on the Alliance Boots transaction and issue a new forecast by late July or early August.
June 24- Walgreen Co, the largest drug retailer in the United States, reported a 15.7 percent rise in quarterly profit, helped by strong growth in prescription sales. Net income rose to $722 million, or 75 cents per share, in the quarter ended May 31, from $624 million, or 65 cents per share, a year earlier. Sales rose 5.9 percent to $19.40 billion.
Paid members of the Arcview Group have committed to investing at least $50,000 into the budding cannabis industry. Members are in Denver hearing pitches from pot start-ups, reports CNBC's Josh Lipton.
June 19- Drugstore operator Rite Aid Corp said higher drug costs and a fall in reimbursement rates would continue into the second quarter, sending it shares down 4.4 percent. Rite Aid's shares have been on a tear for most of the past year, until the company warned on first-quarter profit and cut its full-year earnings forecast earlier this month.
June 19- Drugstore operator Rite Aid Corp's quarterly profit more than halved, hurt by higher-than-expected drug costs and a bigger-than-anticipated fall in reimbursement rates. Rite Aid said a delay in the expected fall in prices of generic medicines raised its drug costs.
The nation's largest drugstore chain, based in Illinois, is under pressure from some of its shareholders to do a deal known as a tax inversion with Alliance Boots Holdings Ltd that would shift Walgreen's tax domicile overseas.
June 5- Drug retailer Rite Aid Corp estimated first-quarter profit much below analysts' expectations due to higher-than-expected drug costs and a bigger-than-expected fall in reimbursement rates. Rite Aid's shares fell as much as 14 percent on Thursday on the New York Stock Exchange.
Incyte CEO Herve Hoppenot, provides insight to his company's progress on cancer research at this year's ASCO conference.
Ariad Pharmaceuticals CEO Dr. Harvey Berger, says investors are responding to his company's better overall picture, and the progress on its leukemia drug Iclusig.
In the U.S., half of all men and a third of all women will develop cancer in their lifetimes. CNBC's Meg Tirrell reports which stocks analysts are eyeing into the conference.
Costco reported third-quarter results below analysts' estimates hurt by an increase in merchandise costs and other expenses.
CNBC's Meg Tirrell reports Sanofi and Eli Lilly announced an agreement to pursue regulatory approval of an over-the-counter version of erectile dysfunction drug Cialis.
CNBC's Meg Tirrell reports on the high cost of drug prices. Ezekial Emanuel, University of Pennsylvania; and Alex Brill, American Enterprise Institute, share their concerns and solutions for the issue.
PTC Therapeutics skyrockets on a recommendation for approval in Europe for its Duchenne Muscular Dystrophy drug. CNBC's Meg Tirrell provides insight to the disease and treatment options. Shane Kovacs, PTC Therapeutics CFO, looks at the move in the stock.
CNBC's Meg Tirrell reports why drugs in the U.S. versus the rest of the world are priced differently.